Dr. Zack Scott previously served on the board of directors for Cianna Medical, Coherex Medical, Evidation Health, Providence Medical Technology, Respicardia, Spiration, and Syapse.
Prior to joining Norwest, Zack was the co-founder and managing partner of Revelation Partners, a dedicated secondary investor specializing in shareholder liquidity and growth capital for healthcare companies. During his time at Revelation Partners, he made notable investments in Omada Health, iRhythm Technologies (IPO), SetPoint Medical, and Respicardia (acquired by Zoll Medical).
Before working in private equity, Zack was a General Surgery resident at Oregon Health & Science University in Portland, Oregon. He earned his M.D. from the University of Texas Health Science Center at San Antonio where he was a member of the AOA Medical Honors Society, and subsequently earned an M.B.A. with a specialized certificate in Health Sector Management from The Fuqua School of Business at Duke University where he was a Fuqua Scholar.
Brian is an experienced life sciences investor who focuses on early to mid-stage companies.
Prior to joining Norwest, Brian worked at Blackstone Life Sciences, where he helped lead over $1.5B of investments across biotech, medical devices, and diagnostics. He was a Board Observer or Alliance Committee Member at 5 companies, working closely with management teams on clinical trials, FDA approval process, and commercial strategy. Brian was previously an Engagement Manager at McKinsey & Company, where he advised companies across the healthcare industry.
Brian has a medical degree from Stanford and MBA from Harvard. His research on prostate cancer, diabetic macular edema, and patient safety has been published in multiple peer-review journals.
Tiba joins Norwest as a biotech investor with 20+ years of research and investment experience.
Based in the San Francisco office, she invests in healthcare with a focus on early to mid-stage companies within the therapeutics sector.
Prior to joining Norwest, Tiba spent over ten years at Novo Holdings A/S, one of the top life sciences investment firms, with offices in the US and Europe. In her previous role, she was responsible for the deployment of ~280M of capital in private biotech, MedTech and HCIT companies. Earlier in her career Tiba was a banker focused on M&A, licensing, and financing transactions involving biotech/pharma.
Tiba attended the University of California Irvine where she received a Bachelor of Science degree in Physics with a Biomedical concentration. She also holds a Ph.D. in Biophysics from the University of California San Francisco, where she also did her Postdoctoral Fellowship. Tiba is also a published author of scientific articles and book chapters in rational drug design.
Trey focuses on venture opportunities in the healthcare sector, including medical devices, diagnostics, biopharmaceuticals, digital health, technology-enabled healthcare services, and healthcare IT.
Before joining Norwest, Trey was a part of the strategy and business development team at Senti Biosciences, a next-generation cell and gene therapy company that is developing gene circuits to reprogram cells with biological logic to sense inputs, compute decisions, and respond to their cellular environments. Previously, Trey held positions with the life sciences group at Wells Fargo Securities in San Francisco and the Pfizer Neuroscience Research Unit in Cambridge, MA.
Trey obtained bachelor of arts degrees in both neuroscience and economics from Dartmouth College. He is currently enrolled in a Masters in Biomedical Informatics at Stanford Medical School through the Honors Cooperative (work/study) Program.
Nathan focuses on growth equity investments in healthcare, including healthcare services, pharma services, healthcare IT, medical devices, and digital health. Nathan is actively involved with Norwest’s investments in American Endovascular & Amputation Prevention, Elligo Health Research, Kyo, Mindful Health Solutions, and RiverMend Health.
Before joining Norwest, Nathan was an analyst in the healthcare investment banking group at J.P. Morgan in San Francisco. In this role, he advised companies across the healthcare sector on mergers & acquisitions, equity financings, and other strategic opportunities. Prior to that, Nathan was in the equity capital markets group at J.P. Morgan in New York, covering healthcare and pricing more than ten initial public offerings.
Nathan holds a bachelor of science in business administration with concentrations in finance and accounting, magna cum laude, from the University of Richmond’s Robins School of Business.
With over 30 years of experience, Casper is a veteran of the medical device and life sciences industry, having led marketing and commercialization efforts for companies that span the healthcare space. He brings extensive operating knowledge to Norwest Venture Partners, where he focuses on mid-to-late-stage investments in consumer and digital health, healthcare IT, medical devices and diagnostics, technology-enabled healthcare services, and specialty pharmaceuticals. He currently serves on the boards of Clever Care Health Plan, Omada Health, Robin Healthcare, Monogram Health, Route 92 Medical, and Science Exchange. Casper was previously on the board of Basis (acquired by Intel), Crossover Health (acquired by Gurnet Point Capital), Intersect ENT (Nasdaq: XENT), iRhythm Technologies (Nasdaq: IRTC), NextHealth Technologies (acquired by Softheon), and Telcare (acquired by BioTelemetry). Casper is also responsible for Norwest’s investment in BillionToOne and Misfit Wearables (acquired by Fossil).
Prior to Norwest, Casper was a Partner at U.S. Venture Partners (USVP) in Menlo Park, where he invested in therapeutic companies from clinical development through commercialization. At USVP, Casper served as a Board member for AtheroMed, Ilypsa (acquired by Amgen), and Valeritas. Over a six-year period, he was actively involved in making and managing investments in more than a dozen companies as a member of the healthcare team. Casper was also a private investor and board member with Innospine, an orthopedic diagnostic company acquired by Kyphon in 2005.
Ryan brings to Norwest Venture Partners more than thirty years of healthcare experience and twenty years as a growth equity and buyout investor. Combining deep medical knowledge and extensive strategic business experience, Ryan focuses on growth equity investments in the healthcare sector in Norwest’s Palo Alto office. Areas in which he invests include healthcare services, pharma services, healthcare IT, and medical products. Ryan’s current investments include American Endovascular, Blue Cloud, Elligo Health Research, Kyo (formerly Gateway Learning Group), Mindful Health Solutions, Onsite Dental, Scratch Financial, and Target RWE. His previous investments include Capsugel (acquired by Lonza), Crossover Health (acquired by Gurnet Point Capital), iCardiac (acquired by ERT), and Rivermend Health.
Prior to joining Norwest, Ryan was a Principal with The Carlyle Group and a Venture Partner with Industry Ventures, where he focused exclusively on healthcare services, pharmaceutical, and medical device investments from large cap buyouts to growth equity and venture.
Ryan focuses on buyout, growth equity and late-stage venture investments in healthcare, including healthcare services, healthcare IT, pharma services and tech, and digital health. He has been actively involved with Norwest’s investments in American Endovascular, Blue Cloud, Elligo Health Research, Kyo (formerly Gateway Learning Group), Mindful Health Solutions, Onsite Dental, Petabyte (acquired by Chewy), Scratch Financial, TARGET PharmaSolutions, Capsugel (acquired by Lonza), Crossover Health (acquired by Gurnet Point Capital), and iCardiac (acquired by ERT).
Before joining Norwest, Ryan was an investment banking analyst in the Leveraged Finance Group at Bank of America Merrill Lynch. In this role, he analyzed and executed mergers and acquisitions, leveraged buyouts, financings, and other business development opportunities across a wide range of industries. Prior to his time at Bank of America Merrill Lynch, Ryan co-founded and ran a dietary supplement company.
Ryan obtained a bachelor of science degree in business management, with a concentration in economics, from Babson College.
